This is the most critical strategic fork in the road. The Ginkgo story is instructive: they burned $6 billion and lost revenue for three straight years trying to build and own the full FAL stack. They are now pivoting to software + orchestration (Cloud Lab). Recursion built automation but their real moat is the 50-petabyte dataset, not the robots. The hardware is being commoditized.
Do NOT build your own FAL in Phase 1 or 2. Be the intelligent orchestration and AI layer. Own the algorithms, the data, and the customer relationships. Partner or access-on-demand for the robotic execution layer. Revisit FAL ownership only at Series B+ when you have $50M+ ARR to justify the CapEx.
Use Syngene, Aragen, GVK Bio as execution partners. LabOS orchestrates their instruments. You own the AI layer and data.
Deploy 3–5 Automata/Opentrons modular pods co-located with CRO partners. "FAL Pods" as a branded sub-service. ₹15–20Cr investment.
Build India's first purpose-built Fully Autonomous Lab in Hyderabad/Bengaluru Genome Valley. License LabOS to others. Infrastructure play.
| Partner Type | Key Names | What They Provide | Our Leverage |
|---|---|---|---|
| CRO (Wet Lab) | Syngene, Aragen, GVK Bio, Lambda | Lab execution, instruments, scientists | AI-driven protocols, data ownership |
| Cloud Lab | Ginkgo Cloud Lab, Arctoris | Remote robotic execution, global access | Orchestration layer + India IP translation |
| Genomics | MedGenome, Strand Life Sciences, 4baseCare | India genomic cohorts, NGS infrastructure | AI interpretation, clinical integration |
| Hardware | Automata, Opentrons, Hamilton | Modular robots, APIs | Workflow orchestration, data capture |
| Cloud | AWS Hyderabad, Azure India, Google Cloud | HPC, storage, AI infrastructure | Negotiated credits, co-sell motions |